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Electrospinning has the capacity to create fibers of
natural or synthetic polymers with dimensions that are
similar to analogous fibers in native tissue.

Mats

consisting of fibers of these sub-micron dimensions have
shown promise in provoking little immune response and in
offering a habitable environment for cell proliferation.
Fibrinogen is a natural protein capable of being

xv
electrospun and offers the benefit of existing as part of
the natural coagulation cascade.

Mats of fibrinogen could

be utilized as possible hemostatic dressings or as an early
scaffold for cell migration for either wound repair or
tissue engineering.

The addition of antibiotic into such a

dressing/scaffold could prevent infection during
healing/incorporation.

The goal of this study was to

determine any effect that the addition of the antibiotic
tetracycline hydrochloride (0%, 2.5%, 5%, 10% by weight)
would have on the mechanical properties of electrospun
fibrinogen (110 mg/mL, 120 mg/mL, and 130 mg/mL
concentrations).

Also, the time release of tetracycline

from electrospun fibrinogen was investigated.

The results

show no significant effect of tetracycline loading on the
mechanical properties of electrospun fibrinogen under the
conditions of this study.

The results of the release study

demonstrate that initial tetracycline release is dependent
upon loading percentage.

The release data also demonstrate

that the amount of tetracycline released is approximately
20-30% of the tetracycline in the original solution and
that the release occurs within approximately 4 hours, with
no significant release thereafter.

This study demonstrates

the feasibility of tetracycline in electrospun fibrinogen

xvi
for the purposes of short term drug release in fibrinogenbased technologies.

Introduction and Background

The goal of tissue engineering is to create analogues
to native tissue for the purpose of replacement or for the
facilitation of repair.

Depending on application, the

structure and composition of these analogues does differ.
Regardless of application, the products of tissue
engineering should not provoke a damaging immune response,
should offer a successfully attractive framework for new or
native cell establishment, and should possess mechanical
and chemical properties similar to the replaced tissue.
The purpose of this study was to incorporate tetracycline
hydrochloride into a fibrinogen scaffold possibly to be
used for in vivo wound repair or as a basis for the in
vitro development of a tissue engineering scaffold.

The

incorporation of an antibiotic such as tetracycline should
assist in the resistance to infection of a maturing wound
dressing or tissue scaffold, but the effects of its
addition on the mechanical properties of the plain
fibrinogen scaffold must be explored.
1

In addition, the

2
release of the tetracycline from the fibrinogen in solution
should be of sufficient concentration and duration to
elicit therapeutic effects.

Tissue Engineering
Tissue engineering is devoted to creating new tissue
that can be accepted and utilized by the body.

A critical

focus of tissue engineering is the framework with which the
cells coexist, the extracellular matrix (ECM).
Communication between the ECM and the cells guides growth,
repair, and morphology1.
ECM analogues that more closely resemble native ECM
will be better tolerated and incorporated in vivo.

One

characteristic of ECM analogue closely related to success
in vivo is fiber size.

When the size of fiber approaches

that of the size of natural components of ECM, cells attach
more easily, readily, and with better success.

Other

critical aspect of successful biomimicking scaffolds is the
minimization of an immune response.

This is affected

greatly by the material from which the scaffold is
constructed.

Although some synthetic polymers can provoke

a negligible immune response, and others still can be

3
degraded and metabolized by the body, greater success is
found in the use of natural polymers such as collagen,
elastin, or fibrinogen.

Collagen is the major component of

native ECM, and elastin exists in some various tissues of
differing mechanical properties (i.e. blood vessels).
Fibrinogen exists in tissues in the early stages of the
repair of damaged tissue, and it yields fibrin, which may
be thought as a ‘provisional matrix’.
The above tissue engineering concepts could be
utilized to create or recreate native tissue such as skin,
cornea, or liver.

For these applications, the most

successful cell scaffold (collagen, elastin, fibrinogen, or
blends) would be the best choice.

If the creation of a

wound dressing is the target, fibrinogen is the obvious
choice.

Not only would it have the advantage of being a

native protein and possibly very acceptable to the native
tissue, but fibrinogen also has the advantage of existing
in the natural coagulation cascade, and so for a bleeding
wound would have both wound healing and hemostatic effects.
The possible incorporation of antibiotic into a wound
dressing might offer better success in healing due to a
reduction in infection.

4
Electrospinning
Electrostatic spinning, or electrospinning, is a
process that utilizes electrostatic forces to create small
diameter fibers from the solution of a polymer.

The first

successful development of electrospinning was in 1934 by
Anton Formhals, who received a patent on the technology.
Formhals electrospun small fibers of cellulose ester from a
solvent of acetone and alcohol.2

The process can generate

generous amounts of fibers at the sub-micron level, smaller
in diameter than any standard extrusion process.
Electrospinning is based on the electrostatic
repulsion within a polymer solution, and the subsequent
electrostatic attraction of the polymer solution (or its
solute) to a grounded electrode.

It is a variant of

electrospraying, where droplets of charged solution are
attracted to a grounded electrode by an external electric
field.

Electrospinning succeeds in the creation of fibers,

rather than droplets that leave the charged solution.
During electrospinning, a solution of polymer forms a
droplet at the end of a capillary tube, or syringe needle,
in this setup.

The droplet is maintained by the surface

tension within the solution, and the applied electric field

5
to the solution forms the droplet into a “Taylor cone”, as
the electric repulsion begins to overcome the surface
tension.

When the electric repulsion within the solution

reaches a critical value, a charged jet of the solution
leaves the Taylor cone.3

This jet, attracted to the

grounded electrode, becomes more concentrated in both
solute and charge density as the solvent evaporates.
Progressively, a thin charged fiber is left behind that
travels to the ground electrode. A diagram of an
electrospinning apparatus is shown below (Figure 1).

Figure 1 : Schematic of electrospinning apparatus

6
The efficacy of this process, as well as the final
fiber product, are affected by a litany of factors,
including, but not limited to solution polymer
concentration, viscosity of solution, voltage between
solution and ground electrode, the distance between the
Taylor cone and the ground electrode, and environmental
conditions such as humidity and temperature.4
Electrospun fibers, because of their small diameters,
have seen much interest not only in the textile field, but
also in that of biomedical research.

The small diameter

fiber is more attractive to cell attachment, because of its
similarity in size to native ECM components, which allow
for the cell to attach to several fibers in a more natural
geometry, rather than the singular flattened orientation
that an attached cell would experience on a large diameter
fiber.

Much research had been conducted with synthetic

resorbable polymers, such as PGA, and natural polymers,
such as collagen and fibrinogen.5,6,7 These studies have
shown the utility of electrospun polymers as scaffolds for
tissue engineering.
In addition, an electrospun mat of synthetic or
natural polymer could be used as a vehicle for drug
delivery.

The target drug could be incorporated into the

7
polymer solution to be spun, and should be uniformly
distributed with the final mat product.

Other technologies

for drug delivery have proven useful (films, slow-release
pelletized formations, polymer disks), but none of these
technologies would enjoy the full cell-friendly benefits of
electrospun materials.8,9

A study by Kenawy et al. utilized

electrospun (and film deposited) synthetic polymers with
incorporated tetracycline and compared the release
characteristics of the same to a film based commercial
product.10

In this study, two synthetic polymers,

poly(ethylene-co-vinylacetate) and poly(lactic acid), and a
blend of the two, were electrospun with 5% tetracycline
hydrochloride.

Samples of these mats were placed in a

buffered solution, and the concentration of tetracycline in
that solution was determined using spectroscopy.

These

polymers were chosen for their success in medical products.
The use of a natural polymer, such as fibrinogen,
should remove much concern of immunogenicity and offer a
more favorable attachment scaffold for in vivo infiltration
of cells in such an application.

8

Fibrinogen
Fibrinogen Structure
Fibrinogen is a large protein of mean molecular weight
33600 kDa, with 95% of the molecular weight attributed to
six amino acid chains (2 Aα, 2 Bβ, and 2 γ chains).

These

six amino chains are arranged in two identical halves, each
half consisting of a single Aα, single Bβ, and single γ
chain, with disulfide bonds linking these chains and the
two AαBβγ halves together (a total of 29 disulfide bonds).
This arrangement often leads to fibrinogen described as a
dimer of the AαBβγ monomer11.

The Aα chain is the largest

of the three chains, with 610 amino acid residues.

The Bβ

chain and γ chain have 461 and 411 residues, respectively.
The Bβ chain and γ chain possess sites of bound
carbohydrates, which account for approximately 5% of the
molecular weight of fibrinogen12.

Extensive data regarding

the sequencing and variance of inter-species fibrinogen
exists, and is beyond the scope of this study, yet, further
research may show some effect of varying sequences on
biochemical activity.

9
Fibrinogen Function and Activity
Fibrinogen is a crucial component of the coagulation
cascade.

When vascular injury occurs, the pathway leading

to blood coagulation is activated.

There exist two

different pathways of coagulation, the intrinsic and
extrinsic pathways.

Both of the pathways involve

sequential activation of different blood components, yet
both arrive at the same destination, the activation of
Factor X to Factor Xa.

It is here that the pathways

converge, and where the common pathway begins.

The common

pathway will be discussed in modest detail, for it is here
where fibrinogen plays an important part as substrate.
diagram of the common pathway is presented in Figure 2.

A

10

Figure 2 : Diagram of coagulation cascade

13

Factor X is activated (Factor Xa) while attached to
the membrane of platelets at the injury site.

The

biochemical function of Factor Xa is that of a serine
protease, a chemical capable of breaking the amino acid
backbone of a protein at a specific location.

Platelet-

attached Factor Xa forms a complex with another blood-borne
component, Factor Va, and, in the presence of calcium,
converts prothrombin to thrombin.

The protease action of

Factor Xa is responsible for this conversion, assisted by

11
the cofactors Va and free calcium.

It is thrombin that

truly controls coagulation, through two distinct actions.
Thrombin activates yet another inactive blood component,
Factor XIII to Factor XIIIa.

Thrombin also cleaves small

peptide chains from the fibrinogen molecule to form soluble
fibrin.12
The action of thrombin on fibrinogen is targeted at
portions of the amino acid backbone of the N-terminal end
of the Aα and Bβ chains of fibrinogen, releasing
fibrinopeptides A and B (FRPA and FRPB).

These

fibrinopeptides are used as indicators of thrombin activity
in laboratory tests.

The absence of these fibrinopeptides

exposes regions on the original fibrinogen molecule (now
fibrin) that form weak hydrogen bonds with like molecules,
forming a loose clot at the injury site.12

The presence of

Factor XIIa (the other thrombin-activated component)
creates covalent bonds between fibrin molecules through
transglutaminase activity, forming an insoluble fibrin
clot14. The now insoluble fibrin clot traps platelets as the
clot accumulates at the injury site.
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Fibrinogen in Tissue Engineering
Because of the native appearance of fibrinogen to
cells of the body, it is possible that fibrinogen could be
utilized as a possible scaffold material for tissue
engineering.

Upon exposure to thrombin, fibrinogen will

yield fibrin, which is the first ECM that healing tissue
will possess.

The fibrin clot offers stability and

structure to the reforming tissue.

The fibrinopeptides

cleaved from fibrinogen signal immune and endothelial cells
to the site of injury, beginning the healing process via
inflammatory response and angiogenesis15.

Other invading

cells begin to digest the provisional fibrin plug and
deposit permanent ECM materials such as collagen.16

More so

than collagen or elastin, and certainly any synthetic
polymer, fibrin should be the ideal healing scaffold for a
wound, since it is the material that tissue would lay down
naturally.

Many studies have been documented showing the

effectiveness of the fibrin matrix is supporting cell
growth and tissue development in musculoskeletal,
epithelial, and urological applications.15

13
Fibrin-Based Technologies
The use of fibrin in wound treatment is storied, with
reporting of such dating to 1909 by Bergel, who used dried
plasma to arrest surgical bleeding.

Patches of pure fibrin

have documented use in the decade to follow.

Early uses of

fibrin included aid to skin grafting and nerve repair.17
The usage of fibrin/fibrinogen products is somewhat clouded
today due to possible transmission of viruses from a
natural blood product, which led to an FDA ban on usage of
pooled fibrinogen concentrates in 1978, leaving American
clinicians with screened blood-bank and autologous blood as
the sole source for fibrin products.18
The current fibrin-based products come in two forms,
dry and liquid.

Both involve simultaneous application of

fibrinogen and thrombin, sometimes with the addition of
Factor XIII and calcium.

The dry product contains

fibrinogen and thrombin, in a freeze-dried or frozen state,
to prevent their reacting.

Stored in air-tight packaging,

this product will yield fibrin upon exposure to air, and
more appropriately, to a wound.

The United States Army has

funded and overseen development of a technology similar to
this for use on the battlefield.19

The liquid product is

delivered as a simultaneous spray upon the wound of
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fibrinogen and thrombin, forming a layer of fibrin that
immediately clots the bleed.

Both technologies show great

efficacy in their ability to deliver concentrations of
these proteins at levels much higher than in blood.20
of these products, however, have their drawbacks.

Both

The dry

sealant has difficulty in handling because of its
activation upon exposure to moisture (even humid air will
begin the reaction).

The liquid version has a long

preparation time because of the necessary dissolution of
components, and therefore would not be optimal in an
emergency setting.

Possible Fibrinogen-Based Technology
If fibrinogen alone is used as the substrate for
fibrin, the stability, ease of use, and longevity of the
product is increased.

Without simultaneous thrombin

administration, the fibrinogen-based product is reliant
upon the thrombin of the wound for the formation of fibrin.
However, the rapid attainment of fibrin with better
handling could make such a product more viable and
practical.

With the technology of electrospinning, an

electrospun fibrinogen wound dressing would have the added
benefit of small fiber diameter which could accelerate

wound healing.
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Wnek et al. demonstrated the feasibility of

electrospinning fibrinogen through the determination of an
appropriate addition (10 X MEM) to the common
electrospinning solvent HFP.10 Once the appropriate solvent
was determined, Wnek et al. electrospun different
concentrations of bovine fibrinogen and measured the fiber
diameters of the final product using SEM microscopy and
image processing software.

Their results indicated that

fiber diameter could be controlled by the adjustment of the
concentration of the spinning solution.
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Tetracycline
Structure and Usage
Tetracyclines encompass a large group of antibiotics
of similar structure and action.

The basic structure is

one of four fused six carbon rings, with several positions
that carry different functional groups depending on the
particular tetracycline species.

The first isolated

tetracycline was chlortetracycline (aureomycin), which was
isolated from Streptomyces aureofaciens in 1948 by Benjamin
Duggar.

The removal of the chlorine from the 7 position of

chlortetracycline yielded tetracycline.

Tetracycline is

considered the first drug that outperformed the natural
drug source from which it originated.
credited to Lloyd Conover in 1955.21

This isolation is
Other members of the

family include oxytetracycline, doxycycline, and
demeclocycline.22
Figure 3.

The structure of tetracycline is shown in

It exists in use as a hydrochloride salt to

increase solubility.
compound.

Tetracycline alone is a basic

Widely used as an oral antibiotic, tetracyclines

had the largest antimicrobial index of known antibiotics
until the 1950s.23
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Figure 3 : Tetracycline structure24

Method of Action
The tetracyclines are mostly bacteriostatic, damaging
the ability of bacteria to reproduce, and are therefore
only effective on those bacteria in stages of reproduction.
Tetracyclines work by inhibiting protein synthesis in
bacteria by binding to the 30S ribosome, thereby halting
the progressive translation of proteins.

Considered very

effective against E. Coli, bacterial ulcers and many
topical infections, tetracyclines find use today in
prophylaxis of acne, topical anti-inflammatory applications
and in dental implants.25
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Project Synopsis
This project explores the effect of tetracycline
hydrochloride on the mechanical properties of electrospun
fibrinogen, and the release of tetracycline from the same.
Tetracycline was added to the solutions at the beginning of
the electrospinning process, and the products of the
electrospinning were subjected to mechanical testing.
Also, time studies were conducted of independent samples of
various preparations of fibrinogen/tetracycline to observe
the release of the drug into a buffered saline solution.
The intended outcomes of this research were to observe and
quantify any change in mechanical properties because of
tetracycline loading, as well as to observe and report the
effects of different fibrinogen concentrations and
tetracycline loading on the release of the drug from the
electrospun mats.

Materials and Methods

Solution Preparation
Due to the small mass of tetracycline hydrochloride to
be added to fibrinogen solutions, stock mixtures of bovine
fibrinogen (Sigma-Aldrich) and tetracycline (Sigma-Aldrich)
in appropriate proportions were prepared in advance.

These

mixtures offered greater precision in solution preparation.
All necessary calculations insured the desired
concentration of fibrinogen in each preparation.

Solutions

of fibrinogen in concentrations of 110 mg/mL, 120 mg/mL,
and 130 mg/mL were prepared with tetracycline weight
percentages of 2.5%, 5%, and 10%.

In addition, pure

fibrinogen solutions were prepared for mechanical analysis
comparison and release controls.

The

fibrinogen/tetracycline mixture was dissolved in a solution
of 90% HFP and 10% 10 X MEM.

The volume of solvent for

each preparation was 6 mL (5.4 mL HFP + 0.6 mL 10 X MEM).
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Electrospinning
In this setup, the solutions of fibrinogen with
varying weight percentages of tetracycline were placed in 5
mL syringes with 18 gauge blunt needles.

A syringe pump

(KD Scientific) was used to maintain a measured flow rate.
The flow rate of the pump was set at 2.0 mL/hr, with minor
adjustments during individual spins for the purpose of
optimizing the spinning process and minimizing waste.

A

high voltage power supply (Spellman CZE100R, Spellman High
Voltage Electronics Corporation) imparted a voltage of 22
kV at the syringe needle.

The electrospun fibers were

collected on a rotating stainless steel mandrel of length
75 mm, width 25 mm, and thickness 4 mm, which also served
as the ground electrode as mentioned earlier.

The mandrel

was rotated at a rotational velocity of approximately 340
rpm, and was also translated before the needle tip with a
rectilinear velocity of approximately 75 mm/s.

The

distance from the needle tip to the mandrel was 10 cm.
The spinning process was conducted in a low-light
environment because of the light-sensitive nature of
tetracycline.

Fibers were collected on the mandrel until

the syringe was devoid of solution, and the

21
fibrinogen/tetracycline mats were removed from the mandrel,
wrapped in heavy foil to minimize light exposure, and
stored at -20 degrees C until needed.

Materials Testing
For materials testing, samples of the preparation were
trimmed into a “dogbone” profile in order to minimize grip
effects, and to create a region of probable failure of
known geometry for calculation of modulus and peak stress.
The samples were 18.6 mm in length and 6.2 mm in width at
their ends (grip attachment), narrowing to width 2.8 mm in
the center of the sample (probable failure region).

The

samples from each preparation (including pure fibrinogen)
were subjected to uniaxial tensile testing using a MTS
Bionix 200 testing station with a strain rate of 10 mm/min,
and with a sampling rate of 20 Hz.

Samples were tested in

both a dry state, and after immersion in PBS for twenty
minutes.
recorded.

Modulus, breaking strain, and peak stress were
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Materials Characterization
Samples of mats spun from each preparation were
prepared for scanning electron microscopy (SEM).

The

samples of each mat were affixed to an electron microscopy
stud.

As the mats are completely dry when spun, the only

necessary step was sputter coating for the imaging process
to be conducted.

SEM images were obtained with a JEOL JSM-

820 microscope at 4000x magnification.

The images obtained

from SEM were scanned into digital computer images.
UTHSCSA ImageTool Version 2.0 was used to determine the
diameters of sixty sample fibers in each preparation for
comparison across concentrations and loading percentages.
In addition, the area of thirty pores was determined with
ImageTool.

These values were averaged and standard

deviations calculated.
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Short Term and Long Term Release Protocol
To study release, samples of each preparation were
obtained.

These samples were harvested from each mat using

a hole punch with diameter 6.35 mm.

The shape of every

sample was identical, but the thickness varied slightly
with each spin, and within each mat.

An average mass for a

single sample punch was determined using the total weight
of samples from a mat, and the number of sample punches.
The samples were placed in 1 mL of PBS at 20 degrees
Celsius.

All samples were independent – a given sample was

studied at only one time point.

There were two time

courses studied for release properties – a short time
course of 128 min (8 time events) and a long time course of
7 days (8 time events).

The short time course allowed for

the collection of data regarding the initial surface
dissolution and early release of tetracycline from the
mats, a behavior overlooked when the first time sample is
at after such dissolution has taken place.

From this

study, that period of rapid dissolution was approximately
an hour in length.

For the short time course, data were

collected at 1, 2, 4, 8, 16, 32, 64, and 128 minutes.

For

the longer time course, data were collected at 1, 4, 14,
24, 48, 72, 120, and 168 hours.

For all release studies,
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there existed triplicate independent samples for each time
event.

This was done to minimize any error from non-

uniformity in the electrospun mats from which the samples
came.

Also, for each short term time event, three 200 µL

samples of the release solution were obtained, in an effort
to avoid any collection error.
from each long term time event.

Four samples were obtained
This offered nine (or

twelve) values for each preparation at a given release
time.

All solution samples for spectrophotometry were

placed in a 96 well culture plate.
Tetracycline concentration in the solutions was
determined using spectrophotometry.

A Molecular Devices

Spectramax Plus spectrophotometer was used to obtain
absorbances.

A standard curve was generated from known

concentrations of tetracycline (0 µg/mL to 150 µg/mL) in PBS
and corresponding absorbances at 360 nanometers.

This

allowed for calculation of tetracycline concentration in
unknown samples.

From the concentration (via absorbance

standard curve), the defined volume in each sample well (1
mL), and the spectrophotometer sample volume (200
microliters), the amount of tetracycline released into
solution by the samples could be determined.

With the

25
assumption that the weight percentage of tetracycline would
be the same in the sample as it were in solution (i.e., if
no disproportionate loss of tetracycline occurred between
syringe to sample), the percentage release could be
calculated with the mass of tetracycline in solution and
the original mass of the sample.

The percentage release,

even with the usage of the average mass calculation
mentioned above, offers a better comparison of behaviors
between preparations, as all spins were not identical,
leading to variation among and within the sample groups.
Such variation was minimized through identical geometry of
samples (6.35 mm circles) and through screening of obvious
incongruities within and among samples (i.e. portions of
mats that were egregiously thin or damaged were not
sampled).

Analytical Methods

Mechanical Data
Analysis of Variance (ANOVA) was utilized to observe
any statistical differences between the mechanical
properties of modulus, breaking strain, and peak stress
across different loading percentages for each
concentration.

These properties for given concentrations

of fibrinogen and tetracycline were compared using analysis
of variance.

Analysis of variance is a statistical test

that compares the variation within a group to the variation
among groups.

A positive ANOVA indicates that the

differences among groups are more substantial than would be
expected by chance alone.

If differences among the sample

groups were found, Tukey’s W was used to determine which
values were significantly different.

Comparisons were made

among preparations of the same fibrinogen concentration
with different tetracycline loading, and among the average
values of preparations with the same fibrinogen

26

27
concentration.

An alpha level of 0.05 was selected a

priori for all statistical tests.

Materials Characterization
ANOVA was also used to determine any difference in
average diameter between preparations of identical
fibrinogen concentrations with different tetracycline
loading percentages.

Again, Tukey’s W was used to

determine which preparations, if any, differed from each
other.

In addition, average fiber diameters of all

preparations of a given fibrinogen concentration were
analyzed to determine any difference among samples of
differing fibrinogen concentrations.

The same procedures

were conducted regarding pore size.

Release
From each time event, the absorbance at 360 nm was
recorded.

A standard curve of absorbance of known

tetracycline concentrations at 360 nm allowed for the
calculation of concentration from absorbance (Figure 39).
Also, from the volume of solution introduced into each
plate well, the mass of tetracycline released into solution
could be determined.

With the mass of tetracycline
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released and the mass of the sample itself, the percentage
of tetracycline released could be calculated.
For the short term release portion of the study, each
of the triplicate samples for a time event was sampled
three times, creating nine data values for each time event.
For the long term release portion of the study, each of the
triplicate samples was sampled four times, creating twelve
data values.

This variation allowed for more precise

measurements to be taken during a period of relatively
lower release. These values were averaged, and standard
deviations were calculated.
The concentration values of each time event were
compared across different tetracycline loading percentages
for a given fibrinogen concentration.

ANOVA was used to

determine if these samples at given time index did differ
significantly – if so, Tukey’s W test was used to assess
which values were significantly different at α = 0.05.
Also, for a given run of release, the data values at all
time indices for a given preparation were analyzed using
ANOVA.

This would indicate if any significant release was

occurring.

Upon significance of differing values, Tukey’s

W test was again analyzed to determine which contiguous
data points did not significantly differ, thereby
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indicating the absence of release at that time, and
possibly beyond.
In an effort to normalize the release curves, the
percentage of tetracycline released was calculated.

This

allowed for a more illustrative comparison between
different preparations, rather than simple concentration in
the release solution.

The percentage data was used to

compare all preparations to each other (using ANOVA and
possible ancillary tests), as these data were independent
of the mass of tetracycline in the sample.
Those fibrinogen samples without tetracycline showed
no change over time in release solution absorbance in
preliminary testing.

Also, the standard curve for

absorbance was obtained with solutions of known
concentration of tetracycline in PBS.

Therefore, the data

obtained by spectrophotometry were already controlled for
presence of fibrinogen and PBS.

Results

Fiber Diameter and Pore Area
After electrospinning, a small sample of each
preparation was obtained for scanning electron microscopy
(SEM).

Sample photographs follow (Figures 4a-4l).
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Figure 4a : SEM micrograph at 4000x
magnification of 110 mg/mL
fibrinogen with 0% tetracycline by
weight

Figure 4b : SEM micrograph at 4000x
magnification of 110 mg/mL fibrinogen
with 2.5% tetracycline by weight

Figure 4c : SEM micrograph at 4000x
magnification of 110 mg/mL
fibrinogen with 5% tetracycline by
weight

Figure 4d : SEM micrograph at 4000x
magnification of 110 mg/mL fibrinogen
with 10% tetracycline by weight
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Figure 4e : SEM micrograph at 4000x
magnification of 120 mg/mL
fibrinogen with 0% tetracycline by
weight

Figure 4f : SEM micrograph at 4000x
magnification of 120 mg/mL fibrinogen
with 2.5% tetracycline by weight

Figure 4g : SEM micrograph at 4000x
magnification of 120 mg/mL
fibrinogen with 5% tetracycline by
weight

Figure 4h : SEM micrograph at 4000x
magnification of 120 mg/mL fibrinogen
with 10% tetracycline by weight
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Figure 4i : SEM micrograph at 4000x
magnification of 130 mg/mL
fibrinogen with 0% tetracycline by
weight

Figure 4j : SEM micrograph at 4000x
magnification of 130 mg/mL fibrinogen
with 2.5% tetracycline by weight

Figure 4k : SEM micrograph at 4000x
magnification of 130 mg/mL
fibrinogen with 5% tetracycline by
weight

Figure 4l : SEM micrograph at 4000x
magnification of 130 mg/mL fibrinogen
with 10% tetracycline by weight

Figures 4a-4l: SEM micrographs of electrospun fibrinogen with and
without tetracycline

From these micrographs, values for average fiber
diameter and pore size were determined using UTHSCSA
ImageTool.

Tables of fiber diameter data (Table 1) and
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pore area (Table 2) are provided. Average fiber diameter,
average pore area, and standard deviations are provided.

Fiber Diameter (µm)
Mean ± SD
Fibrinogen

Fibrinogen

Fibrinogen

110 mg/mL

120 mg/mL

130 mg/mL

0 % Tetracycline

0.345 ± 0.086

0.479 ± 0.155

0.695 ± 0.227

2.5 % Tetracycline

0.304 ± 0.112

0.448 ± 0.195

0.669 ± 0.219

5 % Tetracycline

0.299 ± 0.114

0.442 ± 0.157

0.660 ± 0.234

10 % Tetracycline

0.307 ± 0.104

0.452 ± 0.146

0.702 ± 0.238

Table 1 :

Fiber diameter data for fibrinogen/tetracycline preparations
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Pore Area (µm2)
Mean ± SD
Fibrinogen

Fibrinogen

Fibrinogen

110 mg/mL

120 mg/mL

130 mg/mL

0 % Tetracycline

2.475 ± 1.126

5.188 ± 2.037

7.198 ± 1.956

2.5 % Tetracycline

2.919 ± 1.331

5.066 ± 2.272

6.737 ± 2.938

5 % Tetracycline

2.483 ± 1.001

5.237 ± 2.685

6.571 ± 2.963

10 % Tetracycline

2.686 ± 0.910

5.500 ± 2.225

6.740 ± 2.946

Table 2 : Pore area data for fibrinogen/tetracycline preparations
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The following figures present the data in graphical
form.

Error bars account for one standard deviation.
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Figure 5 : Fiber Diameter by fibrinogen concentration and tetracycline
weight percentage
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Figure 6 :

Pore area by fibrinogen concentration and tetracycline
weight percentage

An analysis of variance indicated no significant
difference (α = 0.05) in either fiber diameter (Table 1) or
pore area (Table 2) for varying tetracycline loading
percentages at a given fibrinogen concentration.

However,

an analysis of variance of average values of fiber
diameters for a given fibrinogen concentration showed
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significant differences across concentrations (P < 0.001).
A Tukey’s W showed that each fiber diameter mean was
significantly different pairwise, for each pair of
concentrations (All P < 0.001).

Similarly, an analysis of

variance showed significant differences in the average pore
area values for the differing fibrinogen concentrations (P
< 0.001), and Tukey’s W indicated that each fibrinogen
concentration pore area mean was statistically different
from the others.
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Mechanical Data
From each preparation, samples were obtained for
mechanical testing, under both dry and wet (saturated in
PBS) conditions.
were recorded.

Modulus, breaking strain, and peak stress

Stress is the quotient of the force acting

upon a object and the cross-sectional area of the object,
and provides a normalized force for use in comparing
mechanical behaviors among different materials and
differing shapes.

Peak stress is the highest stress

experienced until the material begins to fail.

Strain is a

measure of deformation of an object while acted upon by an
external force.

Breaking strain is the maximum deformation

of a material before it ruptures.

Modulus is a quantity

that relates the response of a material (strain) to the
application of outside stress.

It is a description of how

stiff or flexible the material is.
illustrate the data.
tests is α = 0.05.

The following graphs

Confidence level for all statistical
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Moduli of Dry Samples
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Figure 7 :

Modulus by Concentration and Percentage Tetracycline (Dry
Sample)

An analysis of variance showed no significant
difference in dry moduli (Figure 7) among different
tetracycline loading percentages for a given fibrinogen
concentration.

However, average values of dry moduli for a

given fibrinogen concentration were significantly different
from each other (P < 0.001).

Tukey’s W demonstrated

significant differences among all average values of
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fibrinogen concentrations (P < 0.001).

These significant

differences indicate that the 130 mg/mL preparations
possess higher moduli than the 120 mg/mL preparations,
which in turn possess higher moduli than the 110 mg/mL
preparations.
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Breaking Strains of Dry Samples
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Figure 8 : Breaking Strain by Concentration and Percentage Tetracycline
(Dry Sample)

An analysis of variance of dry breaking strain data
(Figure 8) showed no significant differences in breaking
strain across tetracycline loading percentages for a given
fibrinogen concentration, nor any significant differences
in breaking strain for differing fibrinogen concentrations.
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Peak Stresses of Dry Samples
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Figure 9 : Peak Stress by Concentration and Percentage Tetracycline
(Dry Sample)

An analysis of variance showed no significant
differences in peak stress due to differing percentages of
tetracycline (Figure 9).

However, ANOVA returned a

significant difference in average peak stress values among
fibrinogen concentrations regardless of loading (P <
0.001), and Tukey’s W found differences between 130 mg/mL
preparations and 110 mg/mL preparations (P < 0.001), as
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well as between 120 mg/mL preparations and 110 mg/mL (P <
0.003).

In each case, the peak stress of dry 110 mg/mL

fibrinogen concentrations was lower.
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Moduli of Wet Samples
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Figure 10 :

Modulus by Concentration and Percentage Tetracycline (Wet
Sample)

An analysis of variance showed no significant
differences in modulus due to differing percentages of
tetracycline for wet samples (Figure 10).

However, ANOVA

returned a significant difference in average modulus among
fibrinogen concentrations regardless of loading (P =
0.002), and Tukey’s W found differences between 120 mg/mL
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preparations and 110 mg/mL preparations (P = 0.002), as
well as between 130 mg/mL preparations and 110 mg/mL (P =
0.01).

In each case, the modulus of wet 110 mg/mL

fibrinogen concentrations was lower.
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Breaking Strains of Wet Samples
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Figure 11 : Breaking Strain by Concentration and Percentage
Tetracycline (Wet Sample)

An analysis of variance showed no significant
differences in breaking strain due to differing percentages
of tetracycline for wet samples (
Figure 11).

However, ANOVA returned a significant

difference in average breaking strain among fibrinogen
concentrations regardless of loading (P = 0.005), and
Tukey’s W found differences between 120 mg/mL preparations
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and 110 mg/mL preparations (P = 0.03), as well as between
130 mg/mL preparations and 110 mg/mL (P = 0.005).

In each

case, the breaking strain of wet 110 mg/mL fibrinogen
concentrations was lower than the other concentrations.
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Peak Stress of Wet Samples
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Figure 12 : Peak Stress by Concentration and Percentage Tetracycline
(Wet Sample)

An analysis of variance showed no significant
differences in peak stress due to differing percentages of
tetracycline for wet samples (Figure 12).

However, ANOVA

returned a significant difference in average peak stress
among fibrinogen concentrations regardless of loading (P =
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0.007), and Tukey’s W found significant differences between
130 mg/mL preparations and 110 mg/mL preparations (P =
0.016), as well as between 120 mg/mL preparations and 110
mg/mL (P = 0.011).

In each case, the peak stress of wet

110 mg/mL fibrinogen was lower.
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Short Term Release
The results for short term release follows for all
preparations of fibrinogen with tetracycline.

For each

fibrinogen concentration (110 mg/mL, 120 mg/mL, and 130
mg/mL), there exist three different preparations, each with
different loading percentages of tetracycline (2.5% w/w, 5%
w/w, 10% w/w).

The results first report differences in

release profiles for different tetracycline loading of a
given fibrinogen concentration.

Then, concentration over

the time course of the release run (1 min to 128 min) is
analyzed to determine when significant release occurred.
The percentage releases among the three preparations are
compared to observe any differences among different loading
of tetracycline.

Then the results are grouped by

tetracycline loading to observe the effects of varying
fibrinogen concentrations.

All analyses will utilize ANOVA

and Tukey’s W, with the a priori significance level of α =
0.05.
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Release from 110 mg/mL Fibrinogen Preparations
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Figure 13 : Concentration versus time 110 mg/mL fibrinogen with
tetracycline hydrochloride (1 min to 128 min)

140
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Figure 13 shows the change in tetracycline
concentration in the release solution over time for 110
mg/mL fibrinogen samples.

Three different loading

percentages of tetracycline are shown.

Analysis of

variance of the tetracycline concentrations at each time
point showed significant difference among the three
tetracycline loading concentrations (all P < 0.001).
Tukey’s W found that, for each time point, the release
concentration of the 10% preparation was significantly
higher than the 5% preparation (all P < 0.001), and that
the release concentration of the 5% preparation was higher
than that of the 2.5% preparation (all P < 0.001).

In

other words, the three profiles in Figure 13 are
significantly different.
For the 110 mg/mL fibrinogen with 2.5% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

However,

Tukey’s W indicated that the only significant difference
between two successive values existed between 4 min and 8
min (P < 0.001).

Therefore, any release after 8 min can

not be considered significant. (See Table 20 in the
Appendix for all pairwise P-values)
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For the 110 mg/mL fibrinogen with 5% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

However,

Tukey’s W found that the only significant differences in
concentration observed between successive time points were
between times 2 min and 4 min (P = 0.004), 4 min and 8 min
(P < 0.001), and between 64 min and 128 min (P = 0.042).
Therefore, there was significant release from 2 min to 8
min and from 64 min to 128 min. (See Table 21 in Appendix
for all pairwise P-values)
For the 110 mg/mL fibrinogen with 10% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

The

significant differences in concentration observed between
contiguous time points by Tukey’s W were between times 2
min and 4 min (P < 0.001), 4 min and 8 min (P = 0.001), 8
min and 16 min (P = 0.02), and 32 min and 64 min (P =
0.042).

This indicated that significant release occurred

from time 2 min to 16 min.

There was further significant

release from 32 min to 64 min. (See Table 22 in Appendix
for all pairwise P-values)
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Release from 110 mg/mL Fibrinogen Preparations
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Figure 14 : Percentage released versus time for 110 mg/mL fibrinogen
with tetracycline hydrochloride (1 min to 128 min)
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Figure 14 shows the percentage release over time from
preparations of 110 mg/mL fibrinogen with three different
tetracycline loading concentrations.

These percentage

release profiles are identical in shape to the
concentration graphs of Figure 13.

The concentrations have

been converted to percentage of tetracycline released by
using the average mass of the sample, and the
concentrations of Figure 13 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
at all time points other than 16 min and 128 min, there
existed significant difference among the samples.
results are provided below in Table 3.

These

At time points

where ANOVA indicated differences among the percentage
values, Tukey’s W was used to find which pairs of
percentages were different. These results are also provided
in Table 3. In short, the percentage release from the
preparation with 10% tetracycline was significantly higher
than the 2.5% preparation for all times when significant
differences were observed.

Also, the 10% preparation also
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was significantly higher than the 5% preparation at times 1
min, 2 min, and 64 min.

At time 4 min, all percentage

release values were significantly different.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences
(Tukey’s W)

1 min

Yes, P < 0.001

10% > 5% (P < 0.001)
10% > 2.5% (P = 0.001)

2 min

Yes, P < 0.001

10% > 5% (P < 0.001)
10% > 2.5% (P = 0.001)

4 min

Yes, P < 0.001

10% > 5% (P < 0.001)
10% > 2.5% (P < 0.001)
5% > 2.5% (P < 0.001)

8 min

Yes, P = 0.006

10% > 2.5% (P = 0.004)

16 min

None

None

32 min

Yes, P = 0.049

10% > 2.5% (P < 0.001)

64 min

Yes, P < 0.001

10% > 5% (P < 0.001)
10% > 2.5% (P < 0.001)

128 min

None

None

Table 3 : P – values for ANOVA and Tukey’s W for 110 mg/mL samples (1
min to 128 min)
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Release from 120 mg/mL Fibrinogen Preparations
Concentration

120 mg/mL with 2.5%

120 mg/mL with 5%

120 mg/mL with 10%
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Figure 15 : Concentration versus time 120 mg/mL fibrinogen with
tetracycline hydrochloride (1 min to 128 min)

Figure 15 shows the change in tetracycline
concentration in the release solution over time for 120
mg/mL fibrinogen samples.

Three different loading
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percentages of tetracycline are shown.

Analysis of

variance of the tetracycline concentrations at each time
point showed significant difference among the three
tetracycline loading concentrations (all P < 0.001).
Tukey’s W found that, for each time point, the release
concentration of the 10% preparation was significantly
higher than the 5% preparation (all P < 0.001), and that
the release concentration of the 5% preparation was higher
than that of the 2.5% preparation (all P < 0.001).

In

other words, the three profiles in Figure 15 are
significantly different.
For the 120 mg/mL fibrinogen with 2.5% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

However,

Tukey’s W indicated that only significant difference
between two successive values existed between 4 min and 8
min (P < 0.001).

Therefore, significant release only

occurred between 4 min and 8 min. (See Table 23 in the
Appendix for all pairwise P-values)
For the 120 mg/mL fibrinogen with 5% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

However,

Tukey’s W found that the only significant differences in
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concentration observed between successive time points were
between times 2 min and 4 min (P = 0.004), 4 min and 8 min
(P < 0.001), and between 64 min and 128 min (P = 0.042).
Therefore, there was significant release from 2 min to 8
min and from 64 min to 128 min. (See Table 24 in Appendix
for all pairwise P-values)
For the 120 mg/mL fibrinogen with 10% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

The

significant differences in concentration observed between
contiguous time points by Tukey’s W were between times 1
min and 2 min (P < 0.001), 2 min and 4 min (P < 0.001), 4
min and 8 min (P = 0.001), 8 min and 16 min (P = 0.02), and
32 min and 64 min (P = 0.042).

This indicated that

significant release occurred from time 1 min to 16 min.
There was further significant release from 32 min to 64
min. (See Table 25 in Appendix for all pairwise P-values)
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Release from 120 mg/mL Fibrinogen Preparations
Percentage Release
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Figure 16 : Percentage released versus time 120 mg/mL fibrinogen with
tetracycline hydrochloride (1 min to 128 min)

Figure 16 shows the percentage release over time from
preparations of 120 mg/mL fibrinogen with three different
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tetracycline loading concentrations.

These percentage

release profiles are identical in shape to the
concentration graphs of Figure 15.

The concentrations have

been converted to percentage of tetracycline released by
using the average mass of the sample, and the
concentrations of Figure 15 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
at all time points other than 1 min and 128 min, there
existed significant difference among the samples.
results are provided below in Table 4.

These

At time points

where ANOVA indicated differences among the percentage
values, Tukey’s W was used to find which pairs of
percentages were different. These results are also provided
below in Table 4.

In summary, the percentage release from

the preparation with 10% tetracycline was significantly
higher than the 2.5% preparation for all times when
significant differences were observed, with the exception
of time 2 min.

Additionally, the 10% preparation also was

significantly higher than the 5% preparation at times 2

64
min, 32 min, and 64 min.

The 5% preparation was

significantly higher than the 2.5% preparation at 2 min and
4 min.

At time 16 min, all percentage release values were

significantly different, with preparation of higher
tetracycline percentages demonstrating greater release.

Time

Difference
among samples
(ANOVA)

Pairwise Differences
(Tukey’s W)

1 min

None

None

2 min

Yes, P < 0.001

10% > 5% (P < 0.001)
5% > 2.5% (P < 0.001)

4 min

Yes, P < 0.001

10% > 2.5% (P < 0.001)
5% > 2.5% (P = 0.023)

8 min

Yes, P = 0.004

10% > 2.5% (P = 0.004)

16 min

Yes, P < 0.001

10% > 5% (P < 0.001)
10% > 2.5% (P < 0.001)
5% > 2.5% (P = 0.031)

32 min

Yes, P = 0.001

10% > 5% (P = 0.038)
10% > 2.5% (P = 0.003)

64 min

Yes, P = .001

10% > 5% (P < 0.001)
10% > 2.5% (P < 0.001)

128 min

None

None

Table 4 : P – values for ANOVA and Tukey’s W for 120 mg/mL samples (1
min to 128 min)
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Release from 130 mg/mL Fibrinogen Preparations
Concentration

130 mg/mL with 2.5%

130 mg/mL with 5%

130 mg/mL with 10%
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Figure 17 : Concentration versus time 130 mg/mL fibrinogen with
tetracycline hydrochloride (1 min to 128 min)

Figure 17 shows the change in tetracycline
concentration in the release solution over time for 130
mg/mL fibrinogen samples.

Three different loading
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percentages of tetracycline are shown.

Analysis of

variance of the tetracycline concentrations at each time
point showed significant difference among the three
tetracycline loading concentrations (all P < 0.001).
Tukey’s W found that, for each time point, the release
concentration of the 10% preparation was significantly
higher than the 5% preparation (all P < 0.001), and that
the release concentration of the 5% preparation was higher
than that of the 2.5% preparation (all P < 0.001).

In

other words, the three profiles in Figure 17 are
significantly different.
For the 130 mg/mL fibrinogen with 2.5% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

However,

Tukey’s W indicated that only significant difference
between two successive values existed between 16 min and 32
min (P < 0.01).

Therefore, significant release only

occurred between 16 min and 32 min, and no significant
release occurred thereafter. (See Table 26 in the Appendix
for all pairwise P-values)
For the 130 mg/mL fibrinogen with 5% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

However,
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Tukey’s W found that the only significant differences in
concentration observed between successive time points were
between times 2 min and 4 min (P = 0.006), 32 min and 64
min (P < 0.001), and between 64 min and 128 min (P <
0.001).

Therefore, there was significant release from 2

min to 8 min and from 32 min to 128 min. (See Table 27 in
Appendix for all pairwise P-values)
For the 130 mg/mL fibrinogen with 10% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

The

significant differences in concentration observed between
contiguous time points by Tukey’s W were between times 1
min and 2 min (P < 0.001), 2 min and 4 min (P = 0.004), 8
min and 16 min (P < 0.001), and 16 min and 32 min (P =
0.018).

This indicated that significant release occurred

from time 1 min to 4 min.

There was further significant

release from 8 min to 32 min, but no significant release
thereafter. (See Table 28 in Appendix for all pairwise Pvalues)
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Release from 130 mg/mL Fibrinogen Preparations
Percentage Release
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130 mg/mL with 5%

130 mg/mL with 10%

30.00

Percent Released

25.00

20.00

15.00

10.00

5.00

0.00
0

20

40

60

80

100

120

Time (min)
Figure 18 : Percentage released versus time 130 mg/mL fibrinogen with
tetracycline hydrochloride (1 min to 128 min)

Figure 18 shows the percentage release over time from
preparations of 120 mg/mL fibrinogen with three different
tetracycline loading concentrations.

These percentage

release profiles are identical in shape to the

140

concentration graphs of Figure 17.
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The concentrations have

been converted to percentage of tetracycline released by
using the average mass of the sample, and the
concentrations of Figure 17 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
at all time points other than 2 min, 8 min, and 128 min,
there existed significant difference among the samples.
These results are provided below in Table 5.

At time

points where ANOVA indicated differences among the
percentage values, Tukey’s W was used to find which pairs
of percentages were different. These results are also
provided below in Table 5.

In summary, the percentage

release from the preparation with 10% tetracycline was
significantly higher than the 2.5% preparation at times 1
min, 4 min, 64 min, and 128 min, as well as higher than the
5% preparation at times 2 min, and 128 min.

The 5%

preparation was significantly different from the 2.5%
preparation at 1 min and 32 min.

At 1 min, all percentage

release values were significantly different.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences
(Tukey’s W)

1 min

Yes, P < 0.001

10% > 2.5% (P < 0.001)
10% > 5% (P = 0.029)
5% > 2.5% (P= 0.003)

2 min

None

4 min

Yes, P = 0.018

10% > 2.5% (P < 0.001)
5% > 2.5% (P = 0.023)

8 min

None

None

16 min

None

None

32 min

Yes, P = 0.01

5% > 2.5% (P = 0.007)

64 min

Yes, P = 0.025

10% > 2.5% (P = 0.028)

128 min

Yes, P <

None

0.001

10% > 2.5% (P = 0.002)
10% < 5% (P = 0.003)

Table 5 : P – values for ANOVA and Tukey’s W for 130 mg/mL samples (1
min to 128 min)
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Release from 2.5% Tetracycline Preparations
Concentration
110 with 2.5%

120 with 2.5%

130 with 2.5%
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Figure 19 : Concentration versus time for preparations with 2.5%
Tetracycline (1 min to 128 min)

Figure 19 shows the change in tetracycline
concentration in the release solution over time for samples
with 2.5% tetracycline loading.
concentrations are shown.

Three different fibrinogen

Analysis of variance of the
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tetracycline concentrations at each time point showed
significant difference among the three fibrinogen
concentrations (all P < 0.01).

Tukey’s W found

significance differences between pairs of concentrations at
all times.

These results are summarized in Table 6.

In

summary, the 130 mg/mL and 120 mg/mL preparations exhibited
significantly higher release than the 110 mg/mL
preparations at times 1 min and 2 min.

From that point on,

the general trend shows significantly higher release from
the 120 mg/mL preparations.

The 110 mg/mL preparations

also exhibited greater release than the 130 mg/mL
preparations at 8 min, 16 min, 64 min, and 128 min.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

1 min

Yes, P < 0.001

130 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)

2 min

Yes, P < 0.001

130 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)

4 min

Yes, P = 0.009

120 mg/mL > 130 mg/mL (P = 0.006)

8 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P = 0.005)

16 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P = 0.005)

32 min

Yes, P < 0.001

120 mg/mL > 110 mg/mL (P = 0.018)
120 mg/mL > 130 mg/mL (P < 0.001)

64 min

Yes, P < 0.001

128 min

Yes, P < 0.001

110
120
120
110
120
120

mg/mL
mg/mL
mg/mL
mg/mL
mg/mL
mg/mL

>
>
>
>
>
>

130
110
130
130
110
130

mg/mL
mg/mL
mg/mL
mg/mL
mg/mL
mg/mL

(P
(P
(P
(P
(P
(P

<
=
<
=
<
<

0.001)
0.011)
0.001)
0.048)
0.001)
0.001)

Table 6 : P – values for ANOVA and Tukey’s W for release concentration
of samples with 2.5 % tetracycline loading (1 min to 128 min)
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Release from 2.5% Tetracycline Preparations
Percentage Release
110 with 2.5%

120 with 2.5%

130 with 2.5%
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Figure 20 : Percentage released versus time for preparations with 2.5%
tetracycline (1 min to 128 min)

Figure 20 shows the percentage release over time from
preparations with 2.5% tetracycline loading for three
different fibrinogen concentrations.

These percentage

release profiles are identical in shape to the
concentration graphs of Figure 19.

The concentrations have
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been converted to percentage of tetracycline released by
using the average mass of the sample, and the
concentrations of Figure 19 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
only at time points 1 min and 2 min, there existed
significant differences among the samples.
are provided below in Table 7.

These results

At time points where ANOVA

indicated differences among the percentage values, Tukey’s
W was used to find which pairs of percentages were
different. In short, the percentage release from the
preparation with 130 mg/mL fibrinogen exceeded that of 120
mg/mL fibrinogen preparation at times 1 min and 2 min.

In

addition the percentage release from the preparation with
120 mg/mL fibrinogen was greater that of 110 mg/mL
fibrinogen at those times.

From 4 min, the percentage

release from the three preparations was not significantly
different.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)
130
130
120
130
130
120

mg/mL
mg/mL
mg/mL
mg/mL
mg/mL
mg/mL

>
>
>
>
>
>

110
120
110
110
120
110

mg/mL
mg/mL
mg/mL
mg/mL
mg/mL
mg/mL

1 min

Yes, P < 0.001

2 min

Yes, P < 0.001

4 min

None

None

8 min

None

None

16 min

None

None

32 min

None

None

64 min

None

None

128 min

None

None

(P
(P
(P
(P
(P
(P

<
<
<
<
=
=

0.001)
0.001)
0.001)
0.001)
0.040)
0.001)

Table 7 : P – values for ANOVA and Tukey’s W for percentage release of
samples with 2.5 % tetracycline loading (1 min to 128 min)
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Release from 5% Tetracycline Preparations
Concentration
110 with 5%

120 with 5%

130 with 5%
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Concentration (mg/mL)
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Figure 21 : Concentration versus time for preparations with 5%
tetracycline (1 min to 128 min)

Figure 21 shows the change in tetracycline
concentration in the release solution over time for samples
with 5% tetracycline loading.
concentrations are shown.

Three different fibrinogen

Analysis of variance of the

tetracycline concentrations at each time point showed
significant difference among the three fibrinogen
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concentrations (all P < 0.001).

Tukey’s W found

significance differences between pairs of concentrations at
all times.

These results are summarized in Table 8.

In

summary, at times 1 min and 2 min, the 130 mg/mL and 120
mg/mL fibrinogen preparations exhibited greater release
than the 110 mg/mL preparation, with the release from 120
mg/mL exceeded the 130 mg/mL preparation as well.

From

that point on, the general trend shows significantly higher
release from the 120 mg/mL preparations.

The 110 mg/mL

preparations also exhibited greater release than the 130
mg/mL preparations at 16 min and 32 min.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)
130
120
120
130
120
120

mg/mL
mg/mL
mg/mL
mg/mL
mg/mL
mg/mL

>
>
>
>
>
>

110
110
130
110
110
130

mg/mL
mg/mL
mg/mL
mg/mL
mg/mL
mg/mL

(P
(P
(P
(P
(P
(P

=
<
=
<
<
<

0.003)
0.001)
0.050)
0.001)
0.001)
0.001)

1 min

Yes, P < 0.001

2 min

Yes, P < 0.001

4 min

Yes, P < 0.001

120 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P < 0.001)

8 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)

16 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

32 min

Yes, P < 0.001

120 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P = 0.003)

64 min

Yes, P < 0.001

120 mg/mL > 110 mg/mL (P = 0.013)
120 mg/mL > 130 mg/mL (P < 0.001)

128 min

Yes, P < 0.001

120 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P < 0.001)

Table 8 : P – values for ANOVA and Tukey’s W for release concentration
of samples with 5 % tetracycline loading (1 min to 128 min)
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Release from 5% Tetracycline Preparations
Percentage Release
110 with 5%

120 with 5%

130 with 5%
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Figure 22 : Percentage released versus time for preparations with 5%
Tetracycline (1 min to 128 min)

Figure 22 shows the percentage release over time from
preparations with 5% tetracycline loading for three
different fibrinogen concentrations.

These percentage

release profiles are identical in shape to the
concentration profiles of Figure 21.

The concentrations

81
have been converted to percentage of tetracycline released
by using the average mass of the sample, and the
concentrations of Figure 21 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
at all times other than 64 min and 128 min, there existed
significant difference among the samples.
are provided below in Table 9.

These results

At time points where ANOVA

indicated differences among the percentage values, Tukey’s
W was used to find which pairs of percentages were
different. In short, the percentage release from the
preparation with 130 mg/mL fibrinogen exceeded that of 110
mg/mL fibrinogen preparation at times 1 min, 2 min and 4
min.

In addition the percentage release from the

preparation with 120 mg/mL fibrinogen was greater that of
110 mg/mL fibrinogen at those times.

At 8 min and 16 min,

the percentage release from the 110 mg/mL was significantly
greater than from the 130 mg/mL.

At 32 min, the release

from 120 mg/mL exceeded 130 mg/mL.

There were no

significant differences in percentage release after 32 min.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

1 min

Yes, P < 0.001

130 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)

2 min

Yes, P < 0.001

130 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P = 0.050)
120 mg/mL > 110 mg/mL (P < 0.001)

4 min

Yes, P = 0.001

130 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)

8 min

Yes, P = 0.004

110 mg/mL > 130 mg/mL (P = 0.003)

16 min

Yes, P = 0.002

110 mg/mL > 130 mg/mL (P = 0.002)

32 min

Yes, P = 0.002

64 min

None

None

128 min

None

None

120 mg/mL > 130 mg/mL (P = 0.050)

Table 9 : P – values for ANOVA and Tukey’s W for percentage release of
samples with 5 % tetracycline loading (1 min to 128 min)
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Release from 10% Tetracycline Preparations
Concentration
110 with 10%

120 with 10%

130 with 10%
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Figure 23 : Concentration versus time for preparations with 10%
Tetracycline (1 min to 128 min)

Figure 23 shows the change in tetracycline
concentration in the release solution over time for samples
with 10% tetracycline loading.
concentrations are shown.

Three different fibrinogen

Analysis of variance of the

tetracycline concentrations at each time point showed
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significant difference among the three fibrinogen
concentrations (all P < 0.001).

Tukey’s W found

significance differences between pairs of concentrations at
all times.

These results are summarized in Table 10.

In

summary, the 120 mg/mL fibrinogen preparations exhibited
significantly greater release at all times.

In addition,

at all times other than 2 min and 4 min, the 110 mg/mL
fibrinogen preparations exhibited greater release than the
130 mg/mL preparations.
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Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

1 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P = 0.001)

2 min

Yes, P < 0.001

120 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P < 0.001)

4 min

Yes, P < 0.001

120 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P < 0.001)

8 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P = 0.001)

16 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

64 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

128 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
120 mg/mL > 110 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

Time

32 min

Table 10 : P – values for ANOVA and Tukey’s W for release concentration
of samples with 10 % tetracycline loading (1 min to 128 min)
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Release from 10% Tetracycline Preparations
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Figure 24 : Percentage released versus time for preparations with 10%
tetracycline (1 min to 128 min)

Figure 24 shows the percentage release over time from
preparations with 10% tetracycline loading for three
different fibrinogen concentrations.

These percentage

release profiles are identical in shape to the
concentration profiles of Figure 23.

The concentrations
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have been converted to percentage of tetracycline released
by using the average mass of the sample, and the
concentrations of Figure 23 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
at all times other than 64 min and 128 min, there existed
significant difference among the samples.
are provided below in Table 11.

These results

At time points where ANOVA

indicated differences among the percentage values, Tukey’s
W was used to find which pairs of percentages were
different. In short, the percentage release from the
preparation with 120 mg/mL fibrinogen exceeded that of 110
mg/mL and 130 mg/mL fibrinogen preparation at times 1 min
and 2 min.

At 8 min and beyond, the percentage releases

from the 110 mg/mL and 120 mg/mL were significantly greater
than from the 130 mg/mL, but not significantly different
from each other.

There were no significant differences in

percentage release at 4 min.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

1 min

Yes, P = 0.007

120 mg/mL > 130 mg/mL (P = 0.009)
120 mg/mL > 110 mg/mL (P = 0.025)

2 min

Yes, P < 0.001

120 mg/mL > 110 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P = 0.008)

4 min

None

None

8 min

Yes, P = 0.002

120 mg/mL > 130 mg/mL (P = 0.005)
110 mg/mL > 130 mg/mL (P = 0.007)

16 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.001)
110 mg/mL > 130 mg/mL (P = 0.014)

32 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P = 0.004)

64 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

128 min

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

Table 11 : P – values for ANOVA and Tukey’s W for percentage release of
samples with 10% tetracycline loading (1 min to 128 min)
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Long Term Release
The data for long term release (1 hr to 168 hr)
follows for all preparations.

As with the short term

release, there exist three fibrinogen concentrations (110
mg/mL, 120 mg/mL, and 130 mg/mL), each with three different
loading percentages of tetracycline (2.5% w/w, 5% w/w, 10%
w/w).

First any differences in release profiles for

different tetracycline loading of a given fibrinogen
concentration are reported.

Then, concentration over the

time course of the release run (1 hr to 168 hr) is analyzed
to determine when significant release occurred.

Then the

results are grouped by tetracycline loading to observe the
effects of varying fibrinogen concentrations.

All analyses

will utilize ANOVA and Tukey’s W, with the a priori
significance level of α = 0.05.
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Concentration Results (Long Term)
All Preparations
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Figure 25 : Concentrations of all preparations over time 168 hours

Figure 25 shows release solution concentrations of all
preparations over time 168 hours.
omitted for clarity.

The error bars have been

The general trend shows that

concentrations at time events increase with increasing
tetracycline loading, and decrease with increasing
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fibrinogen concentration (fiber diameter).

However, the

statistics only validate one of these assertions.

ANOVA

observed differences among concentrations at all times (all
P < 0.05) – however, Tukey’s W only showed significant
differences between concentration values of pairs that were
of different tetracycline concentrations.

For example, two

preparations of identical tetracycline loading (110 mg/mL
with 5% tetracycline and 120 mg/mL with 5% tetracycline)
would not have significantly different concentrations in
their release solutions at any particular time point in the
run.

Significant differences were only seen when the

tetracycline weight percentages differed.

Tables replete

with P-values of these comparisons can be found in the
Appendix.

Individual figures for each fibrinogen

concentration and each tetracycline percentage follow.
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Release from 110 mg/mL Fibrinogen
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Figure 26 : Concentration versus time 110 mg/mL fibrinogen with
tetracycline hydrochloride (1 hr to 168 hr)

Figure 26 shows the change in tetracycline
concentration in the release solution over time for 110
mg/mL fibrinogen samples.

Three different loading

percentages of tetracycline are shown.

Analysis of

variance of the tetracycline concentrations at each time
point showed significant difference among the three
tetracycline loading concentrations (all P < 0.001).
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Tukey’s W found that, for each time point, the release
concentration of the 10% preparation was significantly
higher than the 5% preparation (all P < 0.001), and that
the release concentration of the 5% preparation was higher
than that of the 2.5% preparation (all P < 0.001).
Therefore, the three profiles in Figure 26 are
significantly different.
For the 110 mg/mL fibrinogen with 2.5% tetracycline,
ANOVA revealed that the concentrations from 1 hr to 168 hr
were not significantly different.

This indicates no

significant release during the duration of this run (no
release after 1 hour).
For the 110 mg/mL fibrinogen with 5% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

However,

Tukey’s W found that the only significant differences in
concentration were observed between 1 hour and all times
greater than 24 hours.

Since no concentrations after 24

hours were judged significantly different from the 24
value, no significant release can be reported after 24
hours. (See Table 29 in Appendix for all pairwise P-values)
For the 110 mg/mL fibrinogen with 10% tetracycline,
ANOVA revealed that the concentrations from 1 hr to 168 hr

94
were not significantly different.

This indicates no

significant release during the duration of this run (no
release after 1 hour).
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Release from 110 mg/mL Fibrinogen
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Figure 27 : Percentage released versus time for 110 mg/mL fibrinogen
with tetracycline hydrochloride (1 hr to 168 hr)

Figure 27 shows the percentage release over time from
preparations of 110 mg/mL fibrinogen with three different
tetracycline loading concentrations.

These percentage

release profiles are identical in shape to the
concentration profiles of Figure 26.

The concentrations

have been converted to percentage of tetracycline released
by using the average mass of the sample, and the
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concentrations of Figure 26 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
at only time point 1 hour, there existed significant
difference among the samples.
below in Table 12.

These results are provided

At time points where ANOVA indicated

differences among the percentage values, Tukey’s W was used
to find which pairs of percentages were different. These
results are also provided in Table 12.

The percentage

release between 110 mg/mL preparations of different
tetracycline loadings differed only at 1 hour.

At 1 hour,

the 2.5% tetracycline and 10 % tetracycline preparations
exhibited greater release than the 5% tetracycline
preparation.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences
(Tukey’s W)

1 hr

Yes, P < 0.001

2.5% > 5% (P < 0.001)
10% > 5% (P < 0.001)

4 hr

None

None

14 hr

None

None

24 hr

None

None

48 hr

None

None

72 hr

None

None

120 hr

None

None

168 hr

None

None

Table 12 : P – values for ANOVA and Tukey’s W for 110 mg/mL samples of
different tetracycline loading (1 min to 128 min)
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Release from 120 mg/mL Fibrinogen
Concentration
120 w/ 2.5%
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Figure 28 : Concentration versus time 120 mg/mL fibrinogen with
tetracycline hydrochloride (1 hr to 168 hr)

Figure 28 shows the change in tetracycline
concentration in the release solution over time for 120
mg/mL fibrinogen samples.

Three different loading

percentages of tetracycline are shown.

Analysis of

variance of the tetracycline concentrations at each time
point showed significant difference among the three
tetracycline loading concentrations (all P < 0.001).
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Tukey’s W found that, for each time point, the release
concentration of the 10% preparation was significantly
higher than the 5% preparation (all P < 0.001), and that
the release concentration of the 5% preparation was higher
than that of the 2.5% preparation (all P < 0.001).
Therefore, the three profiles in Figure 28 are
significantly different.
For the 120 mg/mL fibrinogen with 2.5% tetracycline,
ANOVA revealed that the concentrations from 1 hr to 168 hr
were significantly different (P = 0.035).

However, Tukey’s

W returned no significant differences between any values.
This indicates no significant release can be inferred over
the duration of this run (no release after 1 hour).
For the 120 mg/mL fibrinogen with 5% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

However,

Tukey’s W found that the only significant differences in
concentration were observed between 48 hours and 1 hour.
Since no concentrations after 48 hours were judged
significantly different from the 48 hour value, no
significant release can be reported after 48 hours. (See
Table 30 in Appendix for all pairwise P-values)
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For the 120 mg/mL fibrinogen with 10% tetracycline,
ANOVA revealed that the concentrations from 1 hr to 168 hr
were significantly different (P = 0.031).

However, Tukey’s

W returned no significant differences between any values.
This indicates no significant release can be inferred over
the duration of this run (no release after 1 hour).
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Release from 120 mg/mL Fibrinogen
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Figure 29 : Percentage released versus time for 120 mg/mL fibrinogen
with tetracycline hydrochloride (1 hr to 168 hr)

Figure 29 shows the percentage release over time from
preparations of 120 mg/mL fibrinogen with three different
tetracycline loading concentrations.

These percentage

release profiles are identical in shape to the
concentration profiles of Figure 28.

The concentrations

have been converted to percentage of tetracycline released
by using the average mass of the sample, and the
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concentrations of Figure 28 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
at no time points did there exist significant differences
among the samples.

Therefore, all 120 mg/mL fibrinogen

preparations exhibited similar percentage release.
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Release from 130 mg/mL Fibrinogen
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Figure 30 : Concentration versus time 130 mg/mL fibrinogen with
tetracycline hydrochloride (1 hr to 168 hr)

Figure 30 shows the change in tetracycline
concentration in the release solution over time for 130
mg/mL fibrinogen samples.

Three different loading

percentages of tetracycline are shown.

Analysis of

variance of the tetracycline concentrations at each time
point showed significant difference among the three
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tetracycline loading concentrations (all P < 0.001).
Tukey’s W found that, for each time point, the release
concentration of the 10% preparation was significantly
higher than the 5% preparation (all P < 0.001), and that
the release concentration of the 5% preparation was higher
than that of the 2.5% preparation (all P < 0.001).
Therefore, the three profiles in Figure 30 are
significantly different.
For the 130 mg/mL fibrinogen with 2.5% tetracycline,
ANOVA revealed that the concentrations from 1 hr to 168 hr
were significantly different (P = 0.045).

However, Tukey’s

W returned no significant differences between any values.
This indicates no significant release can be inferred over
the duration of this run (no release after 1 hour).
For the 130 mg/mL fibrinogen with 5% tetracycline,
ANOVA revealed that the concentrations from 1 min to 128
min were significantly different (P < 0.001).

However,

Tukey’s W found that the only significant differences in
concentration were observed between times after 24 hours
and 1 hour.

Since no concentrations after 24 hours were

judged significantly different from the 24 hour value, no
significant release can be reported after 24 hours. (See
Table 30 in Appendix for all pairwise P-values)
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For the 130 mg/mL fibrinogen with 10% tetracycline,
ANOVA revealed that the concentrations from 1 hr to 168 hr
were significantly different (P = 0.031).

This indicates

no significant release can be inferred over the duration of
this run (no release after 1 hour).
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Release from 130 mg/mL Fibrinogen
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Figure 31 : Percentage released versus time for 130 mg/mL fibrinogen
with tetracycline hydrochloride (1 hr to 168 hr)

Figure 31 shows the percentage release over time from
preparations of 130 mg/mL fibrinogen with three different
tetracycline loading concentrations.

These percentage

release profiles are identical in shape to the
concentration graphs of Figure 30.

The concentrations have

been converted to percentage of tetracycline released by
using the average mass of the sample, and the
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concentrations of Figure 30 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
at no time points did there exist significant differences
among the samples.

Therefore, all 130 mg/mL fibrinogen

preparations exhibited similar percentage release.
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Long Term Release
Release from 2.5% Tetracycline Preparations
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Figure 32 : Concentration versus time for preparations with 2.5%
tetracycline over 168 hours

Figure 32 shows the tetracycline concentration of the
release solution over time 168 hours for fibrinogen
preparations with 2.5% tetracycline loading.

Three

200

different fibrinogen concentrations are shown.
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Analysis of

variance of the tetracycline concentrations at each time
point showed significant difference among the three
fibrinogen concentrations at all times other than 4 hours
(all P < 0.05).

Tukey’s W found significance differences

between pairs of concentrations at all times other than 4
hours.

These results are summarized in Table 13.

In

summary, the 120 mg/mL fibrinogen preparations exhibited
significantly greater release than 130 mg/mL fibrinogen at
all times other than 4 hours.

In addition, at 14 hours,

the 120 mg/mL fibrinogen preparation expressed significant
greater release than the 110 mg/mL preparation.

Also, at 1

hour, 24 hours, and 48 hours, the 110 mg/mL fibrinogen
preparation expressed significantly higher release than the
130 mg/mL preparations.

110

Time

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

1 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.005)
110 mg/mL > 130 mg/mL (P < 0.001)

4 hr

None

None

14 hr

Yes, P = 0.002

120 mg/mL > 110 mg/mL (P = 0.003)
120 mg/mL > 130 mg/mL (P = 0.013)

24 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P = 0.008)

48 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P = 0.013)

72 hr

Yes, P = 0.006

120 mg/mL > 130 mg/mL (P = 0.005)

120 hr

Yes, P = 0.023

120 mg/mL > 130 mg/mL (P = 0.034)

168 hr

Yes, P = 0.008

120 mg/mL > 130 mg/mL (P = 0.008)

Table 13 : P – values for ANOVA and Tukey’s W for release concentration
of samples with 2.5 % tetracycline loading (1 hr to 168 hr)
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Release from 2.5% Tetracycline Preparations
Percentage Release
110 w/ 2.5%

120 w/ 2.5%

130 w/ 2.5%

40

Percentage Released

35
30
25
20
15
10
5
0
0

20

40

60

80

100

120

140

160

180

Time (hours)

Figure 33 : Percentage release versus time for preparations with 2.5%
tetracycline over 168 hours

Figure 33 shows the percentage release over time from
preparations with 2.5% tetracycline loading for three
different fibrinogen concentrations.

These percentage

release profiles are identical in shape to the
concentration graphs of Figure 32.

The concentrations have

been converted to percentage of tetracycline released by
using the average mass of the sample, and the
concentrations of Figure 32 as indicated in the Methods.
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The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
at times 1 hour, 14 hours, 24 hours, and 48 hours, there
existed significant difference among the samples.
results are provided below in Table 14.

These

At time points

where ANOVA indicated differences among the percentage
values, Tukey’s W was used to find which pairs of
percentages were different.

In short, significant

differences in percentage released were seen at 1 hour, 14
hours, 24 hours, and 48 hours.

At each of these times, the

110 mg/mL preparations exhibited higher release than the
130 mg/mL preparations.

In addition, at time 1 hour, the

110 mg/mL preparations had significantly higher release
than the 120 mg/mL preparations.
differences were found.

No other significant
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Time

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

1 hr

Yes, P < 0.001

110 mg/mL > 120 mg/mL (P = 0.003)
110 mg/mL > 130 mg/mL (P < 0.001)

4 hr

None

None

14 hr

Yes, P = 0.017

110 mg/mL > 130 mg/mL (P = 0.013)

24 hr

Yes, P = 0.018

110 mg/mL > 130 mg/mL (P = 0.013)

48 hr

Yes, P = 0.028

110 mg/mL > 130 mg/mL (P = 0.022)

72 hr

None

None

120 hr

None

None

168 hr

None

None

Table 14 : P – values for ANOVA and Tukey’s W for percentage release of
samples with 2.5 % tetracycline loading (1 hr to 168 hr)
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Concentration Results (Long Term)
Release from 5% Tetracycline Preparations
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Figure 34 : Concentration versus time for preparations with 5%
tetracycline over 168 hours

Figure 34 shows the tetracycline concentration of the
release solution over time 168 hours for fibrinogen
preparations with 5% tetracycline loading.
fibrinogen concentrations are shown.

Three different

Analysis of variance

of the tetracycline concentrations at each time point
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showed significant difference among the three fibrinogen
concentrations at all times (all P < 0.05).

Tukey’s W

found significance differences between pairs of
concentrations at all times.
in Table 15.

These results are summarized

In summary, the 110 mg/mL fibrinogen

preparations exhibited significantly greater release than
130 mg/mL fibrinogen at all times.

In addition, at all

times other than 4 hours, the 120 mg/mL fibrinogen
preparations expressed significant greater release than the
130 mg/mL preparations.

Also, at 120 hours and 168 hours,

the 110 mg/mL fibrinogen preparation expressed
significantly higher release than the 120 mg/mL
preparations.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

1 hr

Yes, P = 0.008

120 mg/mL > 130 mg/mL (P = 0.042)
110 mg/mL > 130 mg/mL (P = 0.008)

4 hr

Yes, P = 0.004

110 mg/mL > 130 mg/mL (P = 0.003)

14 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.018)
110 mg/mL > 130 mg/mL (P < 0.001)

24 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.015)
110 mg/mL > 130 mg/mL (P < 0.001)

48 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.005)
110 mg/mL > 130 mg/mL (P < 0.001)

72 hr

Yes, P = 0.003

120 mg/mL > 130 mg/mL (P = 0.044)
110 mg/mL > 130 mg/mL (P = 0.002)

120 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 120 mg/mL (P = 0.008)
110 mg/mL > 130 mg/mL (P < 0.001)

168 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.002)
110 mg/mL > 120 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

Table 15 : P – values for ANOVA and Tukey’s W for release concentration
of samples with 5 % tetracycline loading (1 hr to 168 hr)
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Release from 5% Tetracycline Preparations
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Figure 35: Percentage release versus time for preparations with 5%
tetracycline over 168 hours

Figure 35 shows the percentage release over time from
preparations with 5% tetracycline loading for three
different fibrinogen concentrations.

These percentage

release profiles are identical in shape to the
concentration profiles of Figure 34.

The concentrations

have been converted to percentage of tetracycline released
by using the average mass of the sample, and the
concentrations of Figure 34 as indicated in the Methods.
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The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
there existed significant difference among the samples at
all times.

These results are provided below in Table 16.

At time points where ANOVA indicated differences among the
percentage values, Tukey’s W was used to find which pairs
of percentages were different.

In short, significant

differences in percentage released were seen at all times.
At each of these times, the 110 mg/mL preparations
exhibited higher release than the 130 mg/mL preparations.
In addition, at time 4 hours, 120 hours, and 168 hours the
110 mg/mL preparations had significantly higher release
than the 120 mg/mL preparations.

Also, at times 48 hours,

120 hours, and 168 hours, the 120 mg/mL preparations had
significantly greater release than the 130 mg/mL
preparations.
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Time

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

1 hr

Yes, P = 0.012

110 mg/mL > 130 mg/mL (P = 0.009)

4 hr

Yes, P = 0.004

110 mg/mL > 120 mg/mL (P = 0.004)
110 mg/mL > 130 mg/mL (P = 0.030)

14 hr

Yes, P = 0.001

110 mg/mL > 130 mg/mL (P < 0.001)

24 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)

48 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P = 0.021)

72 hr

Yes, P = 0.004

110 mg/mL > 130 mg/mL (P = 0.003)

120 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 120 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P = 0.010)

168 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 120 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P = 0.022)

Table 16: P – values for ANOVA and Tukey’s W for percentage release of
samples with 5 % tetracycline loading (1 hr to 168 hr)
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Figure 36 : Concentration versus time for preparations with 10%
tetracycline over 168 hours

Figure 36 shows the tetracycline concentration of the
release solution over time 168 hours for fibrinogen
preparations with 10% tetracycline loading.

Three

different fibrinogen concentrations are shown.

Analysis of

variance of the tetracycline concentrations at each time
point showed significant difference among the three
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fibrinogen concentrations at all times (all P < 0.05).
Tukey’s W found significance differences between pairs of
concentrations at all times.
in Table 17.

These results are summarized

In summary, there is a significant trend

across all times.

At all times except 72 hours, the 110

mg/mL preparations exhibited significantly higher release
than the 120 mg/mL preparations, and the 120 mg/ml
preparations exhibited significantly higher release than
the 130 mg/mL preparations.

At 72 hours, the release from

110 mg/mL and 120 mg/mL were not significantly different,
but were both significantly higher than that of the 130
mg/mL preparations.

122

Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 120 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.010)
110 mg/mL > 120 mg/mL (P < 0.001)
110 mg/mL > 130 mg/mL (P < 0.001)

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.015)
110 mg/mL > 120 mg/mL (P = 0.007)
110 mg/mL > 130 mg/mL (P < 0.001)

24 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.006)
110 mg/mL > 120 mg/mL (P = 0.029)
110 mg/mL > 130 mg/mL (P < 0.001)

48 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 120 mg/mL (P = 0.008)
110 mg/mL > 130 mg/mL (P < 0.001)

72 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.035)
110 mg/mL > 130 mg/mL (P < 0.001)

120 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.021)
110 mg/mL > 120 mg/mL (P = 0.014)
110 mg/mL > 130 mg/mL (P < 0.001)

168 hr

Yes, P < 0.001

120 mg/mL > 130 mg/mL (P = 0.009)
110 mg/mL > 120 mg/mL (P = 0.003)
110 mg/mL > 130 mg/mL (P < 0.001)

Time

1 hr

4 hr

14 hr

Table 17 : P – values for ANOVA and Tukey’s W for release concentration
of samples with 10 % tetracycline loading (1 hr to 168 hr)
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Release from 10% Tetracycline Preparations
Percentage Release
110 w/ 10%

120 w/ 10%

130 w/ 10%

35

Percentage Released
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Figure 37: Percentage release versus time for preparations with 10%
tetracycline over 168 hours

Figure 37 shows the percentage release over time from
preparations with 10% tetracycline loading for three
different fibrinogen concentrations.

These percentage

release profiles are identical in shape to the
concentration profiles of Figure 36.

The concentrations

have been converted to percentage of tetracycline released
by using the average mass of the sample, and the
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concentrations of Figure 36 as indicated in the Methods.
The calculation of percentage release serves as a
normalized view of release, independent of mass, and,
therefore allows for a better comparison of release from
different preparations.
Analysis of variance at each time event indicated that
there existed significant difference among the samples at
all times.

These results are provided below in Table 18.

At time points where ANOVA indicated differences among the
percentage values, Tukey’s W was used to find which pairs
of percentages were different.

In short, significant

differences in percentage released were seen at all times.
At each of these times, the 110 mg/mL preparations
exhibited higher release than the 130 mg/mL preparations.
In addition, at time 1 hour, 4 hours, 14 hours, and 168
hours the 110 mg/mL preparations had significantly higher
release than the 120 mg/mL preparations.

Also, at times 4

hours, 24 hours, and 48 hours, the 120 mg/mL preparations
had significantly greater release than the 130 mg/mL
preparations.
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Difference
among samples
(ANOVA)

Pairwise Differences (Tukey’s W)

1 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 120 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P < 0.001)

4 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 120 mg/mL (P = 0.003)

14 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 120 mg/mL (P = 0.043)

24 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P = 0.040)

48 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)
120 mg/mL > 130 mg/mL (P = 0.013)

72 hr

Yes, P = 0.004

110 mg/mL > 130 mg/mL (P = 0.003)

120 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)

168 hr

Yes, P < 0.001

110 mg/mL > 130 mg/mL (P < 0.001)
110 mg/mL > 120 mg/mL (P = 0.021)

Time

Table 18: P – values for ANOVA and Tukey’s W for percentage release of
samples with 10 % tetracycline loading (1 hr to 168 hr)
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Percentage Release (All Preparations)

29

110 w/
2.5%
110 w/ 5%

Percentage Released

27

25

110 w/
10%
120 w/
2.5%
120 w/ 5%

23

21

120 w/
10%
130 w/
2.5%
130 w/ 5%

19

17

130 w/
10%
15
0

50

100
Time (hr)

150
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Figure 38 : Percentage Release over time for all preparations (error
bars excluded for clarity)

Figure 38 presents percentage release data for all
preparations over the long term 168 hour release study.
Error bars have been submitted for clarity.
suggests several trends.

The graph

First, preparations of the same

fibrinogen concentrations are grouped closely and exhibit
similar release.

Secondly, upon viewing these fibrinogen
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concentrations, those preparations of lower fibrinogen
concentration tend to release a greater percentage of
tetracycline over time (110 mg/mL higher than 120 mg/mL,
120 mg/mL higher than 130 mg/mL).

Lastly, the ultimate

percentage released for all preparations is roughly 20% to
30%.
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Percentage Release Statistics
Analyses of variance were performed at each time value
for the percentage release of all preparations.
significant difference among the preparations.

All showed
However,

with two noted exceptions, Tukey’s W only showed pairwise
differences between preparations of fibrinogen
concentration 110 mg/mL and those of 120 mg/mL or 130 mg/mL
fibrinogen.

These differences were not found in every

comparison, but with 36 pairwise comparisons for each time
event, and relatively few significant differences,
individual statements of release differences would be
expansive.

A summary of these differences are listed in

the Appendix.

The exceptions to the above trend occurred

at 1 hour (110 w/ 10% > 110 w/ 5%) and 48 hours (120 w/ 5%
> 130 w/ 10% and 120 w/ 2.5% > 130 w/ 10%).

The data for

percentage release by fibrinogen concentration and by
tetracycline loading was offered separately in earlier
sections.

This analysis is supplied only to offer a more

global perspective.

Discussion

Fiber Diameter and Pore Area
As shown in the results, the addition of tetracycline
in weight percentages of up to 10% has no significant
effect on fiber diameter.

Fiber diameter of electrospun

fibrinogen has been shown to be a function of solution
concentration and these results demonstrate this as well7.
In addition, tetracycline had no significant effect on pore
area, as this is often controlled by fiber diameter.

Mechanical Data
Regardless of the mechanical property measured, the
addition of tetracycline showed no significant effect.

The

modulus of dry samples was dependent on the original
fibrinogen concentration, with higher fibrinogen
concentrations in the electrospinning solution yielding
electrospun mats with stiffer moduli.

This is probably due

to the increase in fiber diameter of the resulting mats
(see fiber diameter data).

The testing of modulus for wet
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preparation showed a similar trend, with differences
between the 110 mg/mL and 120 mg/mL and between 110 mg/mL
and 130 mg/mL being significant.

In each case, the greater

fibrinogen concentration yielded a higher modulus. A
greater sample size may have allowed for more significance
to be seen between 120 mg/mL and 130 mg/mL.

The modulus of

wet fibrinogen was consistently seen as lower than that of
the dry preparation.
There was no significant difference among preparations
in breaking strain.

Although there may appear to be a

trend of increasing breaking strain with increasing
fibrinogen concentration (and fiber diameter), the
variation among samples and the incongruities within
electrospun fibrinogen may have occluded any possible
statistically significant differences.

Wet breaking strain

did exhibit a trend, with increasing fibrinogen
concentration causing an increasing in the strain to break.
The significant difference between 110 mg/mL and 120 mg/mL
and 110 mg/mL and 130 mg/mL lend evidence to the dependence
between breaking strain and fibrinogen concentration.
amazing property of fibrinogen is demonstrated in the
possible ten fold increase in breaking strain when
fibrinogen mats are hydrated.

Although the modulus

An
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decreases with hydration, the material becomes ultimately
more flexible.
The peak stresses of dry preparations were
statistically different, and the 130 mg/mL preparations
were statistically greater than the 110 mg/mL preparations.
A similar result was found in the hydrated preparations,
with significantly higher peak stresses in the 120 mg/mL
and 130 mg/mL preparations, as compared to the 110 mg/mL.
Since the addition of tetracycline had little effect
on the mechanical properties, it can be inferred that the
fibrinogen concentration has a great effect upon the
mechanical properties, for it has a large contribution to
fiber diameter.

A larger diameter fiber will be stronger

in tension and should increase modulus, peak stress, and
breaking strain of materials.

Since all other variables of

the fabrication process were controlled (distance to
mandrel, spinning voltage, mandrel rotation and geometry),
the changes in fiber diameter (and mechanical properties)
should be able to be attributed to solution concentration.
The greater flexibility of hydrated fibrinogen is more
interesting.

The hydration of fibrinogen in PBS has an

obvious effect, increasing flexibility, but the cause is
speculative.

If the technology had been available to
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observe fibers in this wet state, perhaps a change in fiber
geometry, size, or orientation could address this issue.
The difference in wet fibrinogen may also address the
relatively short period of release.

Short Term Release
The effects of tetracycline loading on release can be
easily summarized.

An increase in loading offers a higher

concentration of tetracycline in the release solution.
This is probably because of a greater mass of tetracycline
on the surface of the fibrinogen, which readily dissolves
into solution.

This increase in release concentration was

seen in all preparations.

Upon viewing the short term

release by tetracycline loading percentage, it was seen
that the 120 mg/mL preparations showed greater release than
other preparations.

This result is possibly due to some

incongruities between samples, as the 110 mg/mL
preparations showed higher release than larger diameter
preparations in the long term study.

In summary, higher

tetracycline loading percentage led to higher release
because of increased mass of available tetracycline, and
smaller diameter fibers (except for 120 mg/mL exceptions)
also led to greater release.

The smaller diameter fibers
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offer more surface area for tetracycline to exist and be
readily dissolved.
However, regardless of preparation, the release is
short-lived, often reaching a plateau within minutes, with
no significant release thereafter.
the longer term study.

This was also seen in

With the differing mechanical

behavior of hydrated fibrinogen, a possible explanation is
also the swelling of fibers.
As the fibrinogen hydrates, the individual fibers
could swell, and their increase in diameter could narrow
whatever pores that were available for the tetracycline in
the inner part of the mat to diffuse into solution.

Since

the short term study showed that no more than 25% of the
tetracycline in the mat entered solution, this sealing of
pores and possible sequestration of tetracycline happens
rapidly.

In addition, the higher release percentages seen

from preparation of smaller fiber diameters suggests that
smaller fibers take more time and hydration to reach the
point where their increased size prevents further release
from the interior of the sample.
This relatively low release of tetracycline could have
another cause.

The calculation of percentage release

requires an unsupportable assumption – that the entire
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amount of tetracycline in the electrospinning solution is
incorporated into the final product.

This seems

reasonable, but could not have been verified without
destruction of the sample.

This is a recommendation for a

later study.
The “missing” tetracycline may not exist as a
potential drawback – it could be a benefit.

If the

tetracycline is indeed trapped within the fibrinogen, then
the degradation of fibrinogen would lead to further
release.

Since fibrinogen is insoluble in PBS, this was

not observed.

However, in applications as implantable

tissue scaffolding or wound dressing, there is a possible
rediscovery of the tetracycline.

Upon exposure to thrombin

in blood, the fibrinogen will be cleaved to fibrin, forming
a clot, the “provisional matrix”.

As the tissue remodels

this matrix, replacing it with collagen, the fibrin will be
exposed to enzymes that degrade it.

As the fibrin is

degraded, and the matrix replaced, any tetracycline within
could be liberated.
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Long Term Release
The long term results are similar in profiles to those
of the short term release.

The reliance on loading

percentages is again illustrated.

The data suggests that

concentration is dependent on increasing loading and on
decreasing fibrinogen concentration (fiber diameter).
Although not judged significant at every time point, a
decrease in fiber diameter (per concentration change), did
offer more fiber surface area, so that the early surface
release could be higher.
In many of the preparations, no significant difference
in tetracycline concentration existed between any time
values from 1 hour and 168 hours.
can be confirmed after 1 hour.

Therefore, no release

A purpose of the short term

study was to show the rapid onset of concentration, and it
is apparent that most release occurs before an hour.

There

were samples that showed a significant change (release) up
to 48 hours, yet the general trend was that release had a
shorter duration.

This could also be attributed to the

possibly swelling of the fibers.
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Recommendations for Further Study
This study was not rife with weakness, but in
retrospect, many things could have been improved.

One

major concern is the lack of uniformity with the samples
taken from preparations.

Although each sample had the same

diameter, and was obtained with the same instrument, there
were variations.

The electrospun fibrinogen mat does vary

in thickness, so pieces with identical cross-sectional area
would have different masses.

Using the average mass of the

samples introduced error, as the percentage calculation was
dependent upon mass.

If a particular sample had a mass

quite different from the sample, the variation would be
seen in the percentage results.

Since the release of

tetracycline has been suggested to be restricted to the
surface of the mat (quick cessation of release), the
thickness of the mat is not of the same concern.

These

problems could be remedied by the use of larger sample
pieces for the release study.
Also, a fundamental change in design could address the
above issue, but comes with a price.
conducted with independent samples.

This study was
A given sample of a

preparation offered data at only one time event.

A design

with a larger sample that was repeatedly measured for
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release would reduce variation, but this design would
demand the replacement of harvested release solution,
constant recalculation, and different statistics.
A larger sample size for all facets of the experiment
would undoubtedly reduce variation and show more
significance.

A less conservative ancillary to ANOVA (the

author’s choice was Tukey’s W) might have given more
significant results.

Human error could be lessened if the

spectrophotometry could be accomplished without disturbing
the sample, that is, if the absorbance could be continually
measured while the sample releases its tetracycline.
Also, a method for observing the tetracycline within
the mat would address the surface dissolution theory.
Cross-sections of the mat could possibly be viewed with TEM
or fluorescence microscopy to “see” where the tetracycline
is.

Or, the enzymatic breakdown of fibrinogen mats would

release the tetracycline that is conceivably trapped.

Conclusion

In summary, the presence of tetracycline has minimal
effect on mechanical properties (modulus, peak stress,
breaking strain) and material geometry (fiber diameter and
pore size) of electrospun fibrinogen.

The release data

suggests that release concentration is dependent upon
tetracycline loading percentage (available release
material).

The release concentration is also dependent

upon fiber diameter, as smaller fibers allow for more
release because of their overall increased surface area.
The incomplete release of tetracycline from electrospun
fibrinogen could be a result of the swelling of the fibers,
occluding paths of release from the interior of the mat.
This theory is supported by the higher release percentages
of smaller diameter electrospun mats, which will undergo
more swelling over a longer time period to reach altered
diameters than can prevent release.

These results showed

that tetracycline is a viable addition to applications of
electrospun fibrinogen, and that the release of
138
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tetracycline from the same can be controlled by the factors
of fibrinogen concentration and tetracycline loading
percentage.
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Figure 39 : Standard Curve of Absorbance versus tetracycline
concentration
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Pairwise Differences with P-values
110 w/ 10% > 130 w/ 10%
(P < 0.001)
110 w/ 10% > 130 w/ 5%
(P < 0.001)
110 w/ 10% > 130 w/ 2.5%
(P < 0.001)
110 w/ 10% > 120 w/ 10%
(P < 0.001)
110 w/ 10% > 120 w/ 2.5%
(P < 0.001)
110 w/ 10% > 120 w/ 5%
(P < 0.001)
110 w/ 10% > 110 w/ 5%
(P = 0.044)
110 w/ 2.5% > 130 w/ 10%
(P < 0.001)
110 w/ 2.5% > 130 w/ 5%
(P < 0.001)
110 w/ 2.5% > 130 w/ 2.5%
(P < 0.001)
110 w/ 2.5% > 120 w/ 10%
(P = 0.003)
110 w/ 2.5% > 120 w/ 5%
(P = 0.007)
110 w/ 2.5% > 120 w/ 2.5%
(P = 0.003)
110 w/ 5% > 130 w/ 10%
(P = 0.005)
110 w/ 5% > 130 w/ 5%
(P = 0.005)
110 w/ 10% > 130 w/ 10%
(P < 0.001)
110 w/ 10% > 130 w/ 5%
(P < 0.001)
110 w/ 10% > 120 w/ 2.5%
(P < 0.001)
110 w/ 10% > 130 w/ 10%
(P < 0.001)
110 w/ 10% > 130 w/ 5%
(P < 0.001)
110 w/ 10% > 130 w/ 2.5%
(P = 0.004)
110 w/ 2.5% > 130 w/ 10%
(P = 0.003)
110 w/ 2.5% > 130 w/ 5%
(P = 0.005)
110 w/ 5% > 130 w/ 10%
(P = 0.005)
110 w/ 5% > 130 w/ 5%
(P = 0.007)
110 w/ 10% > 130 w/ 10%
(P < 0.001)
110 w/ 10% > 130 w/ 5%
(P = 0.002)
110 w/ 10% > 130 w/ 2.5%
(P = 0.011)
110 w/ 5% > 130 w/ 10%
(P < 0.001)
110 w/ 5% > 130 w/ 5%
(P = 0.004)
110 w/ 5% > 130 w/ 2.5%
(P = 0.016)
110 w/ 2.5% > 130 w/ 10%
(P = 0.001)
110 w/ 2.5% > 130 w/ 5%
(P = 0.019)
110 w/ 10% > 130 w/ 10%
(P < 0.001)
110 w/ 10% > 130 w/ 5%
(P = 0.002)
110 w/ 10% > 130 w/ 2.5%
(P = 0.049)
110 w/ 5% > 130 w/ 10%
(P < 0.001)
110 w/ 5% > 130 w/ 5%
(P = 0.001)
110 w/ 5% > 130 w/ 2.5%
(P = 0.028)
110 w/ 2.5% > 130 w/ 10%
(P < 0.001)
110 w/ 2.5% > 130 w/ 5%
(P = 0.003)
120 w/ 5% > 130 w/ 10%
(P = 0.042)
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72

120

168

120
110
110
110
110
110
110
110
110
110
110
110
110
110
110
110
110
110
110
110
110
110
110
110

w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/
w/

2.5% > 130 w/ 10%
10% > 130 w/ 10%
10% > 130 w/ 5%
5% > 130 w/ 10%
10% > 130 w/ 10%
10% > 130 w/ 5%
10% > 130 w/ 2.5%
5% > 130 w/ 10%
5% > 130 w/ 5%
5% > 130 w/ 2.5%
2.5% > 130 w/ 10%
2.5% > 130 w/ 5%
5% > 130 w/ 10%
5% > 130 w/ 5%
5% > 130 w/ 2.5%
5% > 120 w/ 10%
5% > 120 w/ 5%
5% > 120 w/ 2.5%
10% > 130 w/ 10%
10% > 130 w/ 5%
10% > 130 w/ 2.5%
10% > 120 w/ 5%
2.5% > 130 w/ 5%
2.5% > 130 w/ 10%

(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P
(P

=
=
=
=
<
<
=
<
<
=
=
=
<
<
<
=
=
=
<
<
=
=
=
=

0.042)
0.006)
0.031)
0.010)
0.001)
0.001)
0.015)
0.001)
0.001)
0.017)
0.003)
0.007)
0.001)
0.001)
0.001)
0.017)
0.004)
0.013)
0.001)
0.001)
0.004)
0.038)
0.004)
0.010)

Table 19 : Pairwise differences at times for long term release
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Time
(min)
1
2
4
8
16
32
64
128

1

2

XX

No
XX

4

8

16

32

0.039 <0.001 <0.001 <0.001
No
<0.001 <0.001 <0.001
XX
<0.001 <0.001 <0.001
XX
No
<0.001
XX
No
XX

64

128

<0.001
<0.001
<0.001
<0.001
0.045
No
XX

<0.001
<0.001
<0.001
<0.001
<0.001
No
No
XX

Table 20 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 110 mg/ml with 2.5% tetracycline

Time
(min)
1
2
4
8
16
32
64
128

1

2

XX

No
XX

4

8

16

32

<0.001 <0.001 <0.001 <0.001
0.004 <0.001 <0.001 <0.001
XX
<0.001 <0.001 <0.001
XX
No
0.018
XX
No
XX

64

128

<0.001
<0.001
<0.001
<0.001
<0.001
No
XX

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.042
XX

Table 21 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 110 mg/ml with 5% tetracycline
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Time
(min)
1
2
4
8
16
32
64
128

1

2

XX

No
XX

4

8

16

32

<0.001 <0.001 <0.001 <0.001
<0.001 <0.001 <0.001 <0.001
XX
0.001 <0.001 <0.001
XX
0.02
<0.001
XX
No
XX

64

128

<0.001
<0.001
<0.001
<0.001
<0.001
0.042
XX

<0.001
<0.001
<0.001
<0.001
<0.001
0.025
No
XX

Table 22 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 110 mg/ml with 10% tetracycline

Time
(min)
1
2
4
8
16
32
64
128

1

2

XX

No
XX

4

8

16

32

0.039 <0.001 <0.001 <0.001
No
<0.001 <0.001 <0.001
XX
<0.001 <0.001 <0.001
XX
No
<0.001
XX
No
XX

64

128

<0.001
<0.001
<0.001
<0.001
0.045
No
XX

<0.001
<0.001
<0.001
<0.001
<0.001
No
No
XX

Table 23 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 120 mg/ml with 2.5% tetracycline

148
Time
(min)
1
2
4
8
16
32
64
128

1

2

XX

No
XX

4

8

16

32

<0.001 <0.001 <0.001 <0.001
0.004 <0.001 <0.001 <0.001
XX
<0.001 <0.001 <0.001
XX
No
0.018
XX
No
XX

64

128

<0.001
<0.001
<0.001
<0.001
No
No
XX

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.042
XX

Table 24 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 120 mg/ml with 5% tetracycline

Time
(min)
1
2
4
8
16
32
64
128

1
XX

2

4

8

<0.001 <0.001 <0.001
XX
<0.001 <0.001
XX
0.001
XX

16

32

64

128

<0.001
<0.001
<0.001
0.02
XX

<0.001
<0.001
<0.001
<0.001
No
XX

<0.001
<0.001
<0.001
<0.001
<0.001
0.042
XX

<0.001
<0.001
<0.001
<0.001
<0.001
0.025
No
XX

Table 25 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 120 mg/ml with 10% tetracycline
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Time
(min)
1
2
4
8
16
32
64
128

1

2

4

8

16

32

64

128

XX

No
XX

No
No
XX

<0.001
0.001
No
XX

<0.001
<0.001
<0.001
No
XX

<0.001
<0.001
<0.001
<0.001
0.010
XX

<0.001
<0.001
<0.001
<0.001
<0.001
No
XX

<0.001
<0.001
<0.001
<0.001
<0.001
0.003
No
XX

Table 26 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 130 mg/ml with 2.5% tetracycline

Time
(min)
1
2
4
8
16
32
64
128

1
XX

2

4

8

0.001 <0.001 <0.001
XX
0.002 <0.001
XX
No
XX

16

32

64

128

<0.001
<0.001
<0.001
0.015
XX

<0.001
<0.001
<0.001
<0.001
No
XX

<0.001
<0.001
<0.001
<0.001
0.015
No
XX

<0.001
<0.001
<0.001
<0.001
<0.001
0.01
No
XX

Table 27 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 130 mg/ml with 5% tetracycline
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Time
(min)
1
2
4
8
16
32
64
128

1
XX

2

4

8

<0.001 0.039 <0.001
XX
0.004 <0.001
XX
No
XX

16

32

64

128

<0.001
<0.001
<0.001
<0.001
XX

<0.001
<0.001
<0.001
<0.001
0.018
XX

<0.001
<0.001
<0.001
<0.001
<0.001
No
XX

<0.001
<0.001
<0.001
<0.001
<0.001
0.002
No
XX

Table 28 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 130 mg/ml with 10% tetracycline

Time
(hr)
1 hr
4 hr
14 hr
24 hr
48 hr
72 hr
120 hr
168 hr

1
hr
XX

4
hr
No
XX

14
hr
No
No
XX

24
hr
0.006
No
No
XX

48
hr
0.004
No
No
No
XX

72
hr
0.006
No
No
No
No
XX

120
168
hr
hr
0.001 <0.001
No
No
No
No
No
No
No
No
No
No
XX
No
XX

Table 29 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 110 mg/ml with 5% tetracycline

151
Time
(hr)
1 hr
4 hr
14 hr
24 hr
48 hr
72 hr
120 hr
168 hr

1
hr
XX

4
hr
No
XX

14
hr
No
No
XX

24
hr
No
No
No
XX

48
hr
0.009
No
No
No
XX

72
hr
No
No
No
No
No
XX

120
hr
No
No
No
No
No
No
XX

168
hr
No
No
No
No
No
No
No
XX

Table 30 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 120 mg/ml with 5% tetracycline

Time
(hr)
1 hr
4 hr
14 hr
24 hr
48 hr
72 hr
120 hr
168 hr

1
hr
XX

4
hr
No
XX

14
hr
No
No
XX

24
hr
0.013
No
No
XX

48
hr
0.031
No
No
No
XX

72
hr
0.027
No
No
No
No
XX

120
hr
0.048
No
No
No
No
No
XX

Table 31 : P-values for Tukey’s W for pairwise comparison of
concentrations over time for 130 mg/ml with 5% tetracycline

168
hr
No
No
No
No
No
No
No
XX
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